This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kurashige, T. Articles by Nakayama, E. Search for Related Content PubMed PubMed Citation Articles by Kurashige, T. Articles by Nakayama, E.

NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma

Correlation with Tumor Grade¹

Departments of Urology [T. K., T. S., T. T., H. K.] and Immunology [Y. No., T. O., E. N.], Okayama University Medical School, Okayama 700-8558, Japan; Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [Y. Na., A. J., G. R., Y-T. C., E. S., L. J. O.]; and Department of Pathology, Cornell University Medical College, New York, New York 10021 [Y-T. C.]

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY-ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The list of human tumor antigens recognized by human CD8 T cells or antibodies has grown rapidly over the past several years (1) . Most of these antigens can be classified according to expression pattern or structural features into one of the following categories: (a) CT³ antigens, e.g., members of the MAGE gene family (2) and NY-ESO-1 (3) ; (b) differentiation antigens, e.g., tyrosinase (4) , gp 100 (5) , and Melan A/MART-1 (6 , 7) ; (c) mutated gene products, e.g., ß-catenin (8) and caspase-8 (9) ; and (d) overexpressed self-antigens, e.g., HER2/neu (10) . Because of their broad representation in cancer and restricted expression in normal tissues, CT antigens have received much attention as potential targets for human cancer vaccine (11) . Of the ten gene or gene families coding for CT antigens (12) , the NY-ESO-1 product appears to be the most immunogenic, inducing a humoral immune response and specific CD8 T-cell reactivity in 50% of patients with advanced NY-ESO-1-expressing tumors (13 , 14) . Immunity to NY-ESO-1 is clearly antigen driven, disappearing with tumor removal or tumor regression (15) .

TCC comprises nearly 90% of primary malignant tumors of the bladder, displaying a broad biological spectrum ranging from superficial to invasive tumors (16) . Tumor grade (G) is based on cellular dysplasia and architectural abnormalities in tumor tissue and is commonly used to classify TCC in terms of malignant potential (17) . High-grade (G3) TCC progresses to muscle invasion more frequently than low-grade (G1 and G2) tumors. Although G1 and G2 tumors often recur, they are less likely to become invasive (18) . Although CIS is a flat superficial tumor, it is classified as a high-grade lesion, which frequently progresses into invasive tumors (17 , 18) .

In the initial description for NY-ESO-1, we found a high frequency of NY-ESO-1 mRNA expression in a small number of TCCs (3) . In this study, we have evaluated NY-ESO-1 expression in a large number of TCCs and have found a correlation between NY-ESO-1 expression and tumor grade. In addition, the sera of patients with TCCs have been screened for antibody against NY-ESO-1, and the antibody response has also been found to be restricted to patients with G3 tumors.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Patients.
TCC specimens were obtained from 62 patients undergoing surgery. The specimens consisted of 54 bladder, 4 ureteral, and 4 renal pelvic TCCs from 49 males and 13 females with a mean age at diagnosis of 65.7 years (range, 25–86 years). Tumor grade was determined according to standard criteria (17) , and TNM classification of TCC was assessed according to the consensus report (19) . Sera from 124 patients (94 males and 30 females) with a mean age at diagnosis of 66.4 years (range, 25–87 years) were tested for serum antibody to NY-ESO-1. All patients, with the exception of patient TCC44, had tumors at the time of serum collection.

RT-PCR Analysis.
mRNA was isolated from frozen tumor specimens using the QuickPrep Micro mRNA Purification kit (Pharmacia, Uppsala, Sweden). Isolated mRNA was subjected to cDNA synthesis using the First-Strand cDNA Synthesis kit (Pharmacia). Primers for RT-PCR were: ESO1-1, 5'-AGTTCTACCTCGCCATGCCT-3'; and ESO1-2, 5'-TCCTCCTCCAGCGACAAACAA-3'. The amplification program for NY-ESO-1 was 1 min at 94°C, 1 min at 60°C, and 1.5 min at 72°C for 35 cycles after denaturing at 94°C for 1 min. These cycles were followed by a 10-min elongation step at 72°C. The PCR products (385 bp) were analyzed on 0.8% agarose gel.

ELISA.
Recombinant NY-ESO-1 protein solution (100 µl/well) at a concentration of 1 µg/ml in coating buffer [15 mM Na₂CO₃, 35 mM NaHCO₃ in distilled water (pH 9.6)] was added to 96-well plates (Nunc, Roskilde, Denmark) and incubated overnight at 4°C. Plates were washed with 0.05% Tween 20/PBS and blocked with 100 µl/well of 5% FCS/PBS for 1 h at room temperature. After washing, patients’ sera (100 µl/well) serially diluted with 5% FCS/PBS were added to the plate and incubated for 2 h at room temperature. After washing, diluted goat antihuman IgG (100 µl/well) labeled with peroxidase (MBL, Nagoya, Japan) was added and incubated for 1 h at room temperature. After washing, substrate solution [50 mM citric acid, 100 mM Na₂HPO₄, 0.03% ortho-phenylenediamine, 0.1% H₂O₂ in distilled water (pH 5.0)] was added in each well and incubated for 15 min at room temperature. After adding 3 M H₂SO₄, plates were read by U-2001 spectrophotometer (TOSOH, Tokyo, Japan).

Immunohistostaining.
Tumor specimens were fixed with buffered formalin and embedded in paraffin. Sections (5 µm) were placed on glass slides, heated at 60°C overnight, and then deparaffinized with xylene and ethanol. For antigen retrieval, tumor specimens mounted on glass slides were immersed into preheated target retrieval solution (DAKO, Carpinteria, CA) for 15 min and allowed to cool for 20 min at room temperature. After the inactivation of endogenous peroxidase, specimens were incubated with 1.5% horse serum in PBS for 30 min at room temperature. mAb specific for NY-ESO-1 (clone ES121) was then added at a concentration of 2.5 µg/ml and incubated overnight at room temperature. After washing, diluted biotinylated antimouse IgG (Vector Laboratories, Burlingame, CA) was applied and incubated for 30 min at room temperature. Avidin labeled with peroxidase (Vector Laboratories) was added after washing and incubated for 30 min at room temperature. Diaminobenzidine tetrahydrochloride was then added for development, followed by counterstaining with hematoxylin solution.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Expression of NY-ESO-1 mRNA in TCC.
Expression of NY-ESO-1 mRNA in TCC specimens was investigated by RT-PCR. As shown in Table 1 , NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. The size of PCR product in tumor was the same as in the T24 human bladder cancer cell line and in testis (Fig. 1A) . The relationship between NY-ESO-1 mRNA expression and pathological and clinical features is shown in Table 1 . NY-ESO-1 mRNA expression was correlated with tumor grade. Higher frequency of NY-ESO-1 mRNA expression was seen in higher grade TCC: 0 of 4 (0%) in G1; 6 of 26 (23%) in G2; and 14 of 32 (44%) in G3. No correlation could be established between NY-ESO-1 expression and age and sex of patients or with presence or absence of muscle invasion. TCC associated with lymph node or systemic metastases appeared to have a higher frequency of NY-ESO-1 expression than nonmetastatic tumors, but the numbers are too small to make a definitive statement.

View larger version (68K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. A, RT-PCR analysis for NY-ESO-1 mRNA expression. mRNA from G1 TCC (Lane 1), G2 TCC (Lanes 2–5), G3 TCC (Lanes 6–8), a human bladder cancer cell line, T24 (Lane 9), and testis (Lane 10) was analyzed for NY-ESO-1 mRNA by RT-PCR. B, H&E staining (left) and immunohistostaining for NY-ESO-1 using mAb ES121 (right) in serial sections of G1, G2, or G3 TCC.

Antibody Response to NY-ESO-1 in TCC Patients.
Sera from 124 TCC patients were analyzed for NY-ESO-1 antibody by ELISA using recombinant NY-ESO-1 protein. Fig. 2 shows titration curves of NY-ESO-1 antibody-positive and -negative sera, and Table 2 summarizes the results. NY-ESO-1 antibody was found in sera from 9 of 72 (12.5%) patients with G3 tumors. No antibody was detected in sera from 52 patients with G1 or G2 tumors or from 23 healthy volunteers. Table 3 lists TNM classification of TCC in patients with NY-ESO-1-positive antibody. Five of 9 seropositive patients had low-stage diseases, including the patients with CIS.

View larger version (26K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. NY-ESO-1 antibody in patients with G3 TCC. Serially diluted sera from 5 patients with G3 TCC (•), serum from an NY-ESO-1-positive patient (), and sera from 5 healthy volunteers () are shown. ELISA tests with recombinant NY-ESO-1 protein are also shown.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

Similar to the association of NY-ESO-1 mRNA expression and high tumor grade, NY-ESO-1 antibody responses appear to be restricted to patients with G3 TCC. Of the 9 patients with NY-ESO-1 antibody, 5 of the patients had CIS, a flat superficial tumor considered to be a progenitor for invasive tumors (17) . BCG has been found to be an effective therapy for patients with CIS and superficial bladder cancer, with prolonged protection from tumor recurrence occurring in a significant proportion of BCG-treated patients (20) . In fact, 3 of 5 NY-ESO-1 antibody-positive CIS patients in our series received BCG therapy and have remained tumor free for 5 months to 5 years. One patient, TCC44, underwent transurethral resection of tumor followed by intravesical BCG instillation in 1995 and has been healthy without tumor recurrence since that time. A serum sample from this patient was first obtained in October 1997 and found to be NY-ESO-1 antibody positive, despite the long tumor-free interval. This observation of persistent NY-ESO-1 antibody in the absence of tumor stands in contrast to our experience with melanoma and other cancer types, where the presence of NY-ESO-1 antibody is clearly antigen driven and disappears with tumor removal or therapy-inducing tumor regression (15) . The basis for: (a) the strong immunogenicity for NY-ESO-1 presented by CIS; (b) the persistence of NY-ESO-1 antibody in CIS patients after successful therapy; and (c) the possibility that NY-ESO-1 immunity might be involved in delaying tumor progression and mediate the therapeutic activity of BCG in superficial bladder cancer is an important topic requiring careful study.

In a recent study by Jäger et al. (14) involving melanoma patients, a humoral immune response to NY-ESO-1 was predictive of a strong CD8 T cell response to NY-ESO-1-derived peptides, as measured by tetramer, enzyme-linked immunospot, and cytotoxicity. We are now conducting a comparable analysis of patients with TCC to determine whether there is a link between the humoral and cellular immune response to NY-ESO-1 in this patient population. Because of the strong immunogenicity of NY-ESO-1, there is considerable interest in vaccine strategies targeting this antigen, and a variety of NY-ESO-1 constructs, including NY-ESO-1 peptides, protein, DNA, and viral and bacterial vectors, are being prepared for clinical evaluation. A recent clinical vaccine trial with HLA-A2-restricted NY-ESO-1 peptides has shown that these peptides can elicit a strong CD8 T-cell response in NY-ESO-1-immunized patients (21) . Because of the high frequency of NY-ESO-1 expression in TCC and the increasing awareness of the limitation of current chemotherapy against TCC, TCC represents a challenging tumor type to test the effectiveness of NY-ESO-1 vaccines.

	ACKNOWLEDGMENTS

 
We thank M. Isobe for excellent technical assistance and J. Mizuuchi for preparation of the manuscript.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by a Grant-in-Aid for Scientific Research on Priority Area (C) from the Ministry of Education, Science, Sports and Culture of Japan.

² To whom requests for reprints should be addressed, at Department of Immunology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Phone: 81-86-235-7188; Fax: 81-86-235-7193; E-mail: noguchi{at}med.okayama-u.ac.jp

³ The abbreviations used are: CT, cancer/testis; TCC, transitional cell carcinoma; RT-PCR, reverse transcription PCR; CIS, carcinoma in situ; BCG, bacillus Calmette-Guérin; TNM, tumor-node-metastasis; mAb, monoclonal antibody.

Received 2/12/01. Accepted 5/ 1/01.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Boon T., Old L. J. Tumor antigens. Curr. Opin. Immunol., 9: 681-683, 1997.[Medline]
2. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC), 254: 1643-1647, 1991.[Abstract/Free Full Text]
3. Chen Y-T., Scanlan M. J., Sahin U., Türeci Ö., Güre A. O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.[Abstract/Free Full Text]
4. Brichard V., Van Pel A., Wölfel T., Wölfel C., De Plaen E., Lethé B., Coulie P. G., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.[Abstract/Free Full Text]
5. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.[Abstract/Free Full Text]
6. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topalian S. L., Miki T., Rosenberg S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.[Abstract/Free Full Text]
7. Coulie P. G., Brichard V., Van Pel A., Wölfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J-P., Renauld J-C., Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.[Abstract/Free Full Text]
8. Robbins P. F., El-Gamil M., Li Y. F., Kawakami Y., Loftus D., Appella E., Rosenberg S. A. A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183: 1185-1192, 1996.[Abstract/Free Full Text]
9. Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med., 186: 785-793, 1997.[Abstract/Free Full Text]
10. Yoshino I., Goedegebuure P. S., Peoples G. E., Parikh A. S., DiMaio J. M., Lyerly H. K., Gazdar A. F., Eberlein T. J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res., 54: 3387-3390, 1994.[Abstract/Free Full Text]
11. Old L. J., Chen Y-T. New paths in human cancer serology. J. Exp. Med., 187: 1163-1167, 1998.[Free Full Text]
12. Chen Y-T., Scanlan M. J., Obata Y., Old L. J. Identification of human tumor antigens by serological expression cloning (SEREX) Devita V. T. Hellman S. Rosenberg S. A. eds. . Cancer Vaccine: Cancer Antigens, : 557-570, J. B. Lippincott Co. Philadelphia 1999.
13. Stockert E., Jäger E., Chen Y-T., Scanlan M. J., Gout I., Karbach J., Arand M., Knuth A., Old L. J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med., 187: 1349-1354, 1998.[Abstract/Free Full Text]
14. Jäger E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P. R., Lee S. Y., Jungbluth A., Jäger D., Arand M., Ritter G., Cerundolo V., Dupont B., Chen Y-T., Old L. J., Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA, 97: 4760-4765, 2000.[Abstract/Free Full Text]
15. Jäger E., Stockert E., Zidianakis Z., Chen Y-T., Karbach J., Jäger D., Arand M., Ritter G., Old L. J., Knuth A. Humoral immune responses of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer, 84: 506-510, 1999.[Medline]
16. Bane B. L., Rao J. Y., Hemstreet G. P. Pathology and staging of bladder cancer. Semin. Oncol., 23: 546-570, 1996.[Medline]
17. Epstein J. I., Amin M. B., Reuter V. R., Mostofi F. K., the Bladder Consensus Conference Committee. The World Health Organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol., 22: 1435-1448, 1998.[Medline]
18. Spruck C. H., III, Ohneseit P. F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y. C., Lerner S. P., Schmütte C., Yang A. S., Cote R., Dubeau L., Nichols P. W., Hermann G. G., Steven K., Horn T., Skinner D. G., Jones P. A. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784-788, 1994.[Abstract/Free Full Text]
19. Urogenital tumours Ed. 5 Sobin L. H. Wittekind C. eds. . TNM Classification of Malignant Tumours, : 183-190, Wiley-Liss, Inc. New York 1997.
20. Lamm D. L. Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. North Am., 19: 573-580, 1992.[Medline]
21. Jäger E., Gnjatic S., Nagata Y., Stockert E., Jäger D., Karbach J., Neumann A., Rieckenberg J., Chen Y-T., Ritter G., Hoffman E., Arand M., Old L. J., Knuth A. Induction of primary NY-ESO-1 immunity: CD8⁺ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1⁺ cancers. Proc. Natl. Acad. Sci. USA, 97: 12198-12203, 2000.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, E. San Jose-Eneriz, L. Garate, L. Cordeu, F. Cervantes, F. Prosper, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia Haematologica, February 1, 2007; 92(2): 153 - 162. [Abstract] [Full Text] [PDF]

				A. O. Gure, R. Chua, B. Williamson, M. Gonen, C. A. Ferrera, S. Gnjatic, G. Ritter, A. J.G. Simpson, Y.-T. Chen, L. J. Old, et al. Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer Clin. Cancer Res., November 15, 2005; 11(22): 8055 - 8062. [Abstract] [Full Text] [PDF]

				K. Nakagawa, Y. Noguchi, A. Uenaka, S. Sato, H. Okumura, M. Tanaka, M. Shimono, A. M. Ali Eldib, T. Ono, N. Ohara, et al. XAGE-1 Expression in Non-Small Cell Lung Cancer and Antibody Response in Patients Clin. Cancer Res., August 1, 2005; 11(15): 5496 - 5503. [Abstract] [Full Text] [PDF]

				M. Li, Y.-H. Yuan, Y. Han, Y.-X. Liu, L. Yan, Y. Wang, and J. Gu Expression Profile of Cancer-Testis Genes in 121 Human Colorectal Cancer Tissue and Adjacent Normal Tissue Clin. Cancer Res., March 1, 2005; 11(5): 1809 - 1814. [Abstract] [Full Text] [PDF]

				H. A. Vaughan, S. Svobodova, D. MacGregor, S. Sturrock, A. A. Jungbluth, J. Browning, I. D. Davis, P. Parente, Y.-T. Chen, E. Stockert, et al. Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1 Clin. Cancer Res., December 15, 2004; 10(24): 8396 - 8404. [Abstract] [Full Text] [PDF]

				S. Fujita, H. Wada, A. A. Jungbluth, S. Sato, T. Nakata, Y. Noguchi, Y. Doki, M. Yasui, Y. Sugita, T. Yasuda, et al. NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6551 - 6558. [Abstract] [Full Text] [PDF]

				Y. Sugita, H. Wada, S. Fujita, T. Nakata, S. Sato, Y. Noguchi, A. A. Jungbluth, M. Yamaguchi, Y.-T. Chen, E. Stockert, et al. NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors Cancer Res., March 15, 2004; 64(6): 2199 - 2204. [Abstract] [Full Text] [PDF]

				E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms Clin. Cancer Res., December 15, 2003; 9(17): 6453 - 6460. [Abstract] [Full Text] [PDF]

				M. Rodolfo, R. Luksch, E. Stockert, Y.-T. Chen, P. Collini, T. Ranzani, C. Lombardo, P. Dalerba, L. Rivoltini, F. Arienti, et al. Antigen-Specific Immunity in Neuroblastoma Patients: Antibody and T-Cell Recognition of NY-ESO-1 Tumor Antigen Cancer Res., October 15, 2003; 63(20): 6948 - 6955. [Abstract] [Full Text] [PDF]

				K. Odunsi, A. A. Jungbluth, E. Stockert, F. Qian, S. Gnjatic, J. Tammela, M. Intengan, A. Beck, B. Keitz, D. Santiago, et al. NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy in Epithelial Ovarian Cancer Cancer Res., September 15, 2003; 63(18): 6076 - 6083. [Abstract] [Full Text] [PDF]

				M. Ayyoub, D. Rimoldi, P. Guillaume, P. Romero, J.-C. Cerottini, D. Valmori, and D. Speiser Tumor-reactive, SSX-2-specific CD8+ T Cells Are Selectively Expanded during Immune Responses to Antigen-expressing Tumors in Melanoma Patients Cancer Res., September 1, 2003; 63(17): 5601 - 5606. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kurashige, T. Articles by Nakayama, E. Search for Related Content PubMed PubMed Citation Articles by Kurashige, T. Articles by Nakayama, E.